NCCN Guideline Updates in Clear-Cell RCC

Opinion
Video

Medical experts will discuss the updated NCCN guidelines favoring ipilimumab + plus nivolumab for patients with favorable risk, including the data supporting this change and its the potential impact on the disease landscape.

Video content above is prompted by the following:

NCCN guidelines have been updated to reflect ipilimumab + plus nivolumab as a preferred regimen in patients with favorable risk. What data supported this change, and how do you see it affecting the disease landscape?

Recent Videos
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Related Content